ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares
ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $77.05, for a total transaction of $96,312.50. Following the transaction, the chief financial officer now directly owns 64,691 shares in the company, valued at approximately $4,984,441.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Brett Sandercock also recently made the following trade(s):
- On Friday, September 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00.
- On Tuesday, August 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.49, for a total transaction of $96,862.50.
ResMed Inc. (RMD) opened at 76.53 on Wednesday. The stock has a 50 day moving average of $76.76 and a 200-day moving average of $73.89. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $81.87. The firm has a market cap of $10.88 billion, a PE ratio of 31.89 and a beta of 0.77.
ResMed (NYSE:RMD) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.02. The company had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 earnings per share. Analysts expect that ResMed Inc. will post $3.05 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 21st. Investors of record on Thursday, August 17th were paid a $0.35 dividend. The ex-dividend date was Tuesday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a yield of 1.83%. ResMed’s payout ratio is 58.09%.
Several analysts have issued reports on RMD shares. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group lowered shares of ResMed from an “outperform” rating to a “neutral” rating in a research report on Tuesday, August 8th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. BMO Capital Markets increased their target price on shares of ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research note on Wednesday, August 2nd. Finally, Bank of America Corporation cut shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $68.50.
Hedge funds have recently bought and sold shares of the business. YorkBridge Wealth Partners LLC lifted its holdings in shares of ResMed by 4.9% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 69 shares in the last quarter. Creative Planning boosted its position in shares of ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 823 shares during the period. Toronto Dominion Bank boosted its position in shares of ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the period. Van ECK Associates Corp boosted its position in shares of ResMed by 7.5% in the first quarter. Van ECK Associates Corp now owns 1,945 shares of the medical equipment provider’s stock valued at $140,000 after acquiring an additional 136 shares during the period. Finally, Huntington National Bank bought a new stake in shares of ResMed in the second quarter valued at about $156,000. Hedge funds and other institutional investors own 60.10% of the company’s stock.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.